You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Androgen Receptor Positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Urothelial Carcinoma Bladder, Androgen Receptor Positive Trial in Providence (Degarelix, Gemcitabine/Cisplatin)

Not yet recruiting
  • Urothelial Carcinoma Bladder
  • Androgen Receptor Positive
  • Providence, Rhode Island
    Lifespan Cancer Institute
May 1, 2023

Breast Cancer Trial in Beijing, Zhengzhou, Changsha (EG017)

Not yet recruiting
  • Breast Cancer
  • Beijing, Benjing, China
  • +2 more
Dec 30, 2022

Salivary Gland Carcinoma Trial in United States (Goserelin Acetate, Pembrolizumab)

Recruiting
  • Salivary Gland Carcinoma
  • Chicago, Illinois
  • +6 more
Sep 22, 2022

Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 Trial in Houston

Recruiting
  • Advanced Breast Carcinoma
  • +17 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Salivary Gland Cancer Trial in Japan (Darolutamide, Goserelin)

Recruiting
  • Salivary Gland Cancer
  • Nagoya, Aichi, Japan
  • +11 more
Jan 21, 2023

Androgen Receptor Positive, Estrogen Receptor Negative, HER2/Neu Negative Trial in United States (drug, other, biological)

Active, not recruiting
Has Results
  • Androgen Receptor Positive
  • +5 more
  • Corona, California
  • +6 more
Jun 8, 2022

Breast Cancer Female, Triple Negative and Androgen Receptor Positive Trial in Caen (Darolutamide, Capecitabine)

Active, not recruiting
  • Breast Cancer Female
  • Triple Negative and Androgen Receptor Positive
  • Caen, France
    Centre François Baclesse
Jan 3, 2022

Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer Trial

Not yet recruiting
  • Hormone Receptor-positive Breast Cancer
  • +2 more
  • Nashville, Tennessee
    Sarah Cannon Research Institute
Oct 5, 2022

Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative Trial in United States (Biomarker Analysis,

Active, not recruiting
Has Results
  • Estrogen Receptor Negative
  • +6 more
  • Biomarker Analysis
  • +3 more
  • Birmingham, Alabama
  • +8 more
Feb 3, 2022

Breast Cancer, Metastasis Trial in New York (Abemaciclib, Bicalutamide)

Recruiting
  • Breast Cancer
  • Metastasis
  • New York, New York
  • +2 more
Oct 14, 2021

Advanced Epithelial Ovarian, Recurrent Epithelial Ovarian, Fallopian Tube Trial in United States (Enzalutamide)

Completed
  • Advanced Epithelial Ovarian
  • +3 more
  • Basking Ridge, New Jersey
  • +5 more
Mar 4, 2022

Prostatic Tumor Trial (AAA617, AAA517, Piflufolastat F 18)

Not yet recruiting
  • Prostatic Neoplasm
  • (no location specified)
Apr 27, 2023

Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer Trial in Madison (18F-DCFPyL)

Recruiting
  • Breast Cancer
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin School of Medicine and Public Health
Oct 18, 2022

Triple Negative Breast Cancer Trial (Seviteronel-D (Seivteronel in combination with dexamethasone), Docetaxel)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Seviteronel-D (Seivteronel in combination with dexamethasone)
  • Docetaxel
  • (no location specified)
Sep 21, 2021

Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7 Trial in Houston (procedure, drug,

Recruiting
  • Invasive Breast Carcinoma
  • +11 more
  • Axillary Lymph Node Dissection
  • +5 more
  • Houston, Texas
  • +1 more
Mar 10, 2022

Breast Cancer Trial in United States (bicalutamide, diagnostic laboratory biomarker analysis, immunohistochemistry staining

Completed
Has Results
  • Breast Cancer
  • San Francisco, California
  • +7 more
Jul 8, 2022

Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma Trial

Not yet recruiting
  • Locally Advanced Salivary Gland Carcinoma
  • +3 more
  • Biopsy
  • +3 more
  • (no location specified)
Jan 10, 2023

Solid Tumor, Androgen Receptor Gene Overexpression Trial in Darlinghurst (SEVI-D (Seviteronel in combination with dexamthasone))

Terminated
  • Solid Tumor
  • Androgen Receptor Gene Overexpression
  • SEVI-D (Seviteronel in combination with dexamthasone)
  • Darlinghurst, New South Wales, Australia
    St Vincent's Hospital
Mar 2, 2021

Metastatic Breast Adenocarcinoma, Breast Cancer Trial in Switzerland (CR1447)

Active, not recruiting
  • Metastatic Breast Adenocarcinoma
  • Breast Cancer
  • Aarau, Switzerland
  • +12 more
Feb 3, 2022

Triple Negative Breast Cancer Trial in United States (GTx-024)

Terminated
Has Results
  • Triple Negative Breast Cancer
  • Fort Lauderdale, Florida
  • +6 more
Oct 29, 2020

Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation Trial in Shanghai (Everolimus, Investigator's Choice of

Not yet recruiting
  • Triple Negative Breast Cancer
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 25, 2023

Prospective Androgen Receptor Signaling Inhibitors Resistance

Not yet recruiting
  • Prostate Cancer
  • +3 more
    • (no location specified)
    Nov 15, 2023

    Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial ([177Lu]Lu-PSMA-617, ARDT, [68Ga]Ga-PSMA-11)

    Not yet recruiting
    • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    • (no location specified)
    Jan 23, 2023

    Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Boston (Apalutamide

    Not yet recruiting
    • Prostate Adenocarcinoma
    • +2 more
    • Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]
    • Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
    • Boston, Massachusetts
      Beth Israel Deaconess Medical Center
    Jan 4, 2023

    Breast Cancer With or Without BRCA Mutation

    Recruiting
    • Breast Cancer
    • Androgen receptor status and BRCA mutation
    • Varanasi, UP, India
      Banaras Hindu University
    Jun 2, 2022